Reporting owner · CIK 0001577014

Rhodes Jason P

Visual SEC Form 4 history across 2 companies, 16 transactions and 3 filings.

DIRDyne Therapeutics, Inc.
Open-market mix
Latest filingAug 17, 2026, 09:30 PM
Filings3Form 4 records
Buying$00 purchases
Selling$65.2M6 sales
Net value−$65.2MBuys minus sells
Companies22 securities
Most recentAug 14, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
1050-5-10Jan 25Feb 266Aug 26

Net value flow

Buys minus sells

Jan 25
$0
Feb 26
$0
Aug 26
−$65.2M

Transaction texture

Ownership and ticket size

Average P/S size$10.9M
Median P/S size$7.5M
Direct6
Indirect10
Aug 14, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern6Derivative Transactionfiling-context6Direct Ownershipfiling-context6Large Holdings Increaseholdings1Large Holdings Reductionholdings3Large Salesize6Repeat Sellerpattern510b5-1 Detectedfiling-context6

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Dyne Therapeutics, Inc. on Aug 14, 2026 valued at $8,061,625.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Dyne Therapeutics, Inc. on Aug 14, 2026 valued at $8,061,625.

Review SEC filing

Associated companies

Visual map of known reporting history

DYNDyne Therapeutics, Inc.7 transactions · latest Aug 17, 2026, 09:30 PMGBIOGeneration Bio Co.9 transactions · latest Feb 09, 2026, 10:41 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
DYNRhodes Jason P
DIR
sale10b5-1322k-$806MS
Cluster Selling Large Holdings Reduction Large Sale+2
−4.0%08/1708/14
DYNRhodes Jason P
DIR
sale10b5-1478k-$1.19BS
Cluster Selling Large Holdings Reduction Large Sale+2
−4.0%08/1708/14
DYNRhodes Jason P
DIR
sale10b5-11.35M-$3.39BS
Cluster Selling Large Holdings Reduction Large Sale+2
−4.0%08/1708/14
DYNRhodes Jason P
DIR
sale10b5-163.6k-$166MS
Cluster Selling Large Sale Repeat Seller+1
−4.0%08/1708/13
DYNRhodes Jason P
DIR
sale10b5-194.4k-$247MS
Cluster Selling Large Sale Repeat Seller+1
−4.0%08/1708/13
DYNRhodes Jason P
DIR
sale10b5-1268k-$703MS
Cluster Selling Large Sale 10b5-1 Detected
−4.0%08/1708/13
GBIORhodes Jason P
DIR
return6.00k—D
Derivative Transaction Direct Ownership
0.0%02/0902/09
GBIORhodes Jason P
DIR
return2.50k—D
Derivative Transaction Direct Ownership
0.0%02/0902/09
GBIORhodes Jason P
DIR
return1.92k—D
Derivative Transaction Direct Ownership
0.0%02/0902/09
GBIORhodes Jason P
DIR
return1.50k—D
Derivative Transaction Direct Ownership
0.0%02/0902/09

Rhodes Jason P Insider Activity FAQ

SEC Form 4 context

Who is Rhodes Jason P?

Rhodes Jason P is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001577014.

Which companies has Rhodes Jason P reported transactions for?

Dyne Therapeutics, Inc., Generation Bio Co.

When was Rhodes Jason P's latest insider buy?

No open-market insider purchase is available for this period.

When was Rhodes Jason P's latest insider sale?

sale at Dyne Therapeutics, Inc. on Aug 14, 2026 valued at $8,061,625.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.